|
|
| | Nilotinib hydrochloride anhydrous Basic information |
| Product Name: | Nilotinib hydrochloride anhydrous | | Synonyms: | Nilotinib hydrochloride anhydrous;4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide hydrochloride (1:1);AMN-107 HCl;Nilotinib hydrochloride anhydrou;Nilotinib hydrochloride anhydrous USP/EP/BP;Nilotinib hydrochloride, 10 mM in DMSO;Nilotinib HCI;Nilotinib hydrochloride | | CAS: | 923288-95-3 | | MF: | C28H23ClF3N7O | | MW: | 565.99 | | EINECS: | | | Product Categories: | | | Mol File: | 923288-95-3.mol |  |
| | Nilotinib hydrochloride anhydrous Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 100 mg/mL (176.68 mM);Ethanol: 2 mg/mL (3.53 mM) | | Water Solubility | Water: Insoluble | | InChIKey | VTGGYCCJUPYZSX-UHFFFAOYSA-N | | SMILES | C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)(=O)C1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1.Cl |
| | Nilotinib hydrochloride anhydrous Usage And Synthesis |
| Uses | Nilotinib Hydrochloride might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product. | | in vivo | Nilotinib hydrochloride (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft[2].
Nilotinib hydrochloride has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon[3].
| Animal Model: | BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)[2] | | Dosage: | 40 mg/kg | | Administration: | Oral gavage; daily; 4 weeks | | Result: | Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line. |
|
| | Nilotinib hydrochloride anhydrous Preparation Products And Raw materials |
|